12701 Commonwealth Drive, Ste. 9 Fort Myers, FL 33913

239.768.0600 www.neogenomics.org

IR Contact: Julie Marshall www.hawkassociates.com

Neogenomics@hawkassociates.com 305.451.1888

NeoGenomics Q1’15 Revenue up 27% to $23M. Adjusted EBITDA $1.5M. Revenue Growth Driven by Strong

Volume Gains and PathLogic Acquisition.

Hawk associates | cHrysler Building | 405 lexington ave, 26tH floor | new york, ny 10174 | tel: 212.541.2465 227 atlantic Boulevard | key largo | florida | 33037 | tel: 305.451.1888

Company Description

NeoGenomics is a pure-play publicly traded laboratory testing service specializing in cancer genetics diagnostic testing. The company’s high-complexity CLIA-certified clinical labs are located in Ft. Myers, FL, Nashville, TN, Irvine, CA and Tampa, FL.

Extensive testing services provided throughout the United States to pathologists, oncologists, other clinicians and hospitals include cytogenetics, fluorescence situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company is fully certified to industry and government standards for genetic specimen testing.

Since its founding in 2001, the company has dedicated itself to providing superior service, faster turnaround times and complete attention to the needs of clients and their patients. The company was the first to launch tech-only FISH services in 2006. In December 2012, the company up-listed to Nasdaq. In 2014 it acquired Path Logic, a testing company based in West Sacramento, CA.

In recent years, the company has aggressively accelerated its pace of innovation adding each year since 2011 an increased number of new tests largely focused on various kinds of cancers. Since January 2012, the company has launched more than 90 new assays for solid tumors and hematopoietic applications. Most recently the company has developed a plasma-based or liquid biopsy urine-based prostate test.

The company’s world-class molecular menu has opened up numerous opportunities to directly serve pharmaceutical companies. It currently has a five-year agreement with Covance with the potential for developing companion diagnostics and expanding into world-wide markets.

The company is focused on growth through expansion of its sales team and adding new clients while improving productivity and decreasing costs. There is heavy emphasis on next generation sequencing and launching new products.

June 16, 2015

Investment Profile Nasdaq: NEO

NEO - Nasdaq

Closing Price (6/15/15) $5.82Market Cap. $351.35 mil.52-Week Range $3.01 - $6.10Average Daily Trading 196,622FY ’14 Diluted EPS $0.02FY ’14 Revenue $87.1 mil.FY ’14 Net Income $1.1 mil.Total Assets (3/31/15) $81.2 mil. Total Liabilities (3/31/15) $22.0 mil.Basic Shares* 60.0 mil.Diluted Shares* 62.7 mil.Insider Ownership 13.6%Est. Public Float 51.8 mil.Fiscal Year End Dec. 31*As of December 31, 2014

Highlights6/16/15NeoGenomics set to join the Russell 3000 Index at the conclusion of the annual reconstitution of Russell indices June 26, according to preliminary list of additions posted June 12. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

6/11/15NeoGenomics launches 12 NeoLab liquid biopsy tests for hematologic diseases.

4/28/15NeoGenomics Q1 revenue up 27% to $23.0M on test volume growth of 28%. Net loss ($761k) vs. net income of $102k. Adjusted EBITDA $1.5M.

2/24/15NeoGenomics 2014 revenue up 31% to $87.1M. Net income $1.1M or $0.02 per share on 29% growth in test volumes. Adjusted EBITDA $9.5M versus $8.5M in 2013. Q4’14 revenue up 36%. Revenue growth includes addition of PathLogic acquisition. Adjusted 2014 EBITDA $9.2M vs. $8.5M in 2013.

10/30/14NeoGenomics Q3’14 revenue up 38% to record $23.2M. Adjusted EBITDA up 21% to $2.6M. Q3 Test volumes up 33%. Net loss ($291k) vs. NI of $900k or $0.02 last year of ($0.02). 9 mo revenue up 29%

07/17/14NEO Q2’14 revenue $20.7M. Net Income 274k, EPS $0.01. Test volumes rise 40% with adjusted EBITDA $2.1M. Average cost per test reduced by 12%. Gross profit margin 49.5%.

The information contained herein is believed to be accurate and is based upon sources which are considered reliable but are not guaranteed by Hawk Associates or the company mentioned. This information is subject to change without notice. Hawk Associates is not a registered broker dealer. Neither Hawk Associates nor the company mentioned assumes any responsibility for the information contained herein. The company featured in this report is a client of Hawk Associates, Inc. This does not represent an offer to buy or sell any security. This profile is protected by applicable copyright laws. No permission is granted to copy, distribute, modify, or post any text, graphics, design or logos.

Investment Profile Nasdaq: NEO

The Market and Competitive Landscape

The field of genetic testing is dominated by a few large public companies that have recently consolidated numerous smaller players in the industry. There are roughly 300 genetic laboratories in the U.S., 80% of which are attached to academic institutions focused on research and development.

Of the 60 commercial labs, 40 - 50 are small privately-run labs and only 10 -20 are large, national or regional labs. The two largest, Quest Diagnostics and LabCorp make up approximately 40% of the cancer genetics testing market. The company believes its superior turnaround times on oncology-related tests give it an important competitive advantage over other labs with significantly longer turnaround times.

In addition, NeoGenomics uses advanced testing algorithms, which often results in more than one test being ordered per sample submitted.

Both cytogenetics and molecular testing are important and highly-accurate diagnostic tools in the fight against cancer. New tests are now being developed rapidly and the market is expanding.

The Outlook

The company characterized its base business test volume in the first quarter of 2015 along with service levels and new account activities as very strong in the quarter.

The company again made excellent market share gains in its base business where test volumes grew 28% compared with last year’s first quarter. However an unusually harsh winter in the northern part of the country impacted growth in January and February.

The company said it was particularly pleased with the excellent progress in its many growth initiatives. The volume of molecular testing, fueled by next generation sequencing, increased by about 52% over last year and emerged as the company’s largest testing category by volume. The company said its approach to molecular testing using targeted profiles by disease category is more widely accepted as a cost effective way to

identify key genetic cancer drivers. Momentum was strong in clinical trials testing with more studies awarded in the quarter than all of last year.

The company stated its disappointment in an “extraordinary reduction” in reimbursement for FISH testing that reduced revenue in the quarter by $2.1 million with a corresponding impact on profit. The company said some large commercial insurers are now in the process of revising their FISH reimbursements upwards. The company said it is working to explain to all payers the importance of adequate reimbursement for FISH testing to ensure that cancer patients are properly diagnosed and treated. The company said its investment in growth through innovation continues with the development and commercialization of new tests.

Company Guidance

The company’s revenue guidance for 2015 is $103M to $108M. This includes an estimated $6M to $8M reduction in revenue as a result of billing the new AMA FISH CPT codes effective Jan. 1, 2015.

Company guidance is based on current organic growth and growth from the PathLogic acquisition. The company reserves the right to adjust this guidance at any time as a result of acquisitions or other strategic initiatives that it may undertake and/or based on the ongoing execution of its business plan.

Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.

(1)  Adjusted EBITDA is defined as earnings before interest, taxes, depreciation, amortization, and non-cash stock-based compensation expense

Website Information

www.neogenomics.org

www.hawkassociates.com

*Base NEO represents organic revenue and test volume growth from legacy business and excludes the impacts from the PathLogic acquisition.

Risk Factors

• Rapid scientific change• Highly competitive market• Changes in government reimbursement policies.